Suppr超能文献

全氟癸酸对大鼠肝脏酰基辅酶A结合蛋白和肝脏脂肪酸结合蛋白的诱导作用。与肝脏长链酰基辅酶A水平缺乏相关性。

Induction of hepatic acyl-CoA-binding protein and liver fatty acid-binding protein by perfluorodecanoic acid in rats. Lack of correlation with hepatic long-chain acyl-CoA levels.

作者信息

Sterchele P F, Vanden Heuvel J P, Davis J W, Shrago E, Knudsen J, Peterson R E

机构信息

School of Pharmacy, University of Wisconsin, Madison 53706.

出版信息

Biochem Pharmacol. 1994 Aug 30;48(5):955-66. doi: 10.1016/0006-2952(94)90366-2.

Abstract

Liver fatty acid-binding protein (L-FABP) and acyl-CoA-binding protein (ACBP) are involved in the intracellular trafficking and compartmentalization of fatty acids and fatty acyl-CoA esters, respectively, in the liver. Both proteins are induced in rat liver by the potent peroxisome proliferator perfluorodecanoic acid (PFDA). While it is believed that the peroxisome proliferator-activated receptor may mediate the responses to peroxisome proliferators by inducing responsive genes, the ligand(s) of this receptor remains unknown. We hypothesized that induction of L-FABP and ACBP in rat liver by PFDA is secondary to accumulation of long-chain acyl-CoA esters. However, neither dose-response nor time-course effects of PFDA on hepatic long-chain acyl-CoA, L-FABP, or ACBP concentrations confirmed this hypothesis. In a dose-response study, PFDA increased hepatic long-chain acyl-CoA concentrations (7 days after treatment) over the dose range of 20-50 mg/kg, whereas it increased ACBP and L-FABP over the wider dose range of 20-65 mg/kg. In the time-course study, PFDA treatment (50 mg/kg) elevated long-chain acyl-CoA esters in the liver beginning on day 3 post-treatment, yet hepatic L-FABP concentrations were increased earlier beginning on day 2 and ACBP was not induced until day 7. To determine if this dissociation of increases in hepatic long-chain acyl-CoA concentrations from increases in hepatic L-FABP and ACBP concentrations could be demonstrated under other conditions, control rats fasted for 24-48 hr were used. Fasting increased hepatic long-chain acyl-CoA levels to a greater extent than PFDA treatment, yet neither L-FABP nor ACBP was induced. We conclude that elevated concentrations of hepatic long-chain acyl-CoAs in PFDA-treated rats are not a major contributor to the induction of L-FABP or ACBP by peroxisome proliferators. A more plausible mechanism is that PFDA induces L-FABP and ACBP by activating the peroxisome proliferator receptor directly rather than indirectly through long-chain acyl-CoA esters.

摘要

肝脏脂肪酸结合蛋白(L-FABP)和酰基辅酶A结合蛋白(ACBP)分别参与肝脏中脂肪酸和脂肪酰基辅酶A酯的细胞内运输和分隔。这两种蛋白质在大鼠肝脏中均由强效过氧化物酶体增殖剂全氟癸酸(PFDA)诱导产生。虽然人们认为过氧化物酶体增殖物激活受体可能通过诱导反应性基因来介导对过氧化物酶体增殖剂的反应,但其受体的配体仍不清楚。我们推测,PFDA在大鼠肝脏中诱导L-FABP和ACBP是长链脂肪酰辅酶A酯积累的继发结果。然而,PFDA对肝脏长链酰基辅酶A、L-FABP或ACBP浓度的剂量反应和时间进程效应均未证实这一假设。在剂量反应研究中,PFDA在20 - 50 mg/kg的剂量范围内增加了肝脏长链酰基辅酶A浓度(治疗7天后),而在20 - 65 mg/kg的更宽剂量范围内增加了ACBP和L-FABP。在时间进程研究中,PFDA治疗(50 mg/kg)在治疗后第3天开始升高肝脏中的长链酰基辅酶A酯,但肝脏L-FABP浓度在第2天就开始升高,而ACBP直到第7天才被诱导。为了确定在其他条件下是否能证明肝脏长链酰基辅酶A浓度升高与肝脏L-FABP和ACBP浓度升高之间的这种解离,使用了禁食24 - 48小时的对照大鼠。禁食比PFDA治疗更能提高肝脏长链酰基辅酶A水平,但L-FABP和ACBP均未被诱导。我们得出结论,PFDA处理的大鼠肝脏中长链酰基辅酶A浓度升高并非过氧化物酶体增殖剂诱导L-FABP或ACBP的主要因素。一个更合理机制是PFDA通过直接激活过氧化物酶体增殖物受体而非通过长链脂肪酰辅酶A酯间接诱导L-FABP和ACBP。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验